MBX Biosciences

MBXPhase 2

MBX Biosciences is focused on developing innovative peptide therapeutics for underserved endocrine and metabolic markets. Enabled by its proprietary PEP platform technology, the company is advancing a pipeline of candidates, with its lead program, canvuparatide, showing positive Phase 1 data and having completed a Phase 2 trial in hypoparathyroidism. The company's mission is to help patients live fuller, healthier lives by translating leading-edge peptide science into convenient, transformative medicines.

Market Cap

$1.4B

Focus

RNA & Gene Therapy

MBX · Stock Price

USD 28.68+5.03 (+21.27%)

Historical price data

AI Company Overview

Technology Platform

Proprietary Precision Endocrine Peptide (PEP) platform that uses advanced chemical modifications (e.g., programmable prodrug technology, fatty acylation) to engineer long-acting, stable analogs of native peptide hormones, aiming to enable convenient dosing and improved pharmacokinetics.

Pipeline Snapshot

7 drugs in pipeline

Drug	Indication	Stage
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 21...	Hypoparathyroidism	Phase 2
MBX 2109	Hypoparathyroidism	Phase 2
MBX 1416 (INN imapextide)	Postbariatric Hypoglycemia	Phase 2
MBX 4291 + Placebo	Obesity	Phase 1
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)	Postbariatric Hypoglycemia	Phase 1

Funding History

Total raised: $154M

IPOUndisclosedUndisclosedMar 15, 2024

Series B$115MFrazier Healthcare PartnersJun 15, 2022

Series A$39MFrazier Healthcare PartnersJun 15, 2020

Opportunities

The primary opportunity is addressing the significant unmet need in hypoparathyroidism with a convenient, once-weekly therapy that could become the new standard of care.

Long-term, the proprietary PEP platform offers a pipeline-in-a-product opportunity, allowing MBX to expand into other large endocrine and metabolic disorder markets with validated hormone targets.

Risk Factors

Key risks include clinical trial failure for its lead candidate canvuparatide in Phase 3, regulatory hurdles, competition from other late-stage therapies, and the need to secure substantial financing to fund late-stage development and potential commercialization.

Competitive Landscape

Main competitors in hypoparathyroidism include the burdensome standard of care (oral calcium/vitamin D) and Ascendis Pharma's once-daily TransCon PTH. MBX aims to differentiate with its once-weekly dosing convenience and its proprietary platform designed to generate best-in-class peptide therapeutics with optimal pharmacokinetic profiles.

Publications

Pipeline